C9orf72 and amyotrophic lateral sclerosis: In the iPSCs-MNs of ALS patients carrying C9orf72 hexanucleotide amplification, researchers studied DNA, RNA, epigenetics and proteins, and then identified novel and known dysfunctional pathways, hoping to find new targeted molecular pathways and target proteins to affect disease progress [62].